Screening and prostate-cancer mortality in a randomized European study.

[1]  David Chia,et al.  Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.

[2]  P. Glasziou,et al.  Cochrane Systematic Review of Colorectal Cancer Screening Using the Fecal Occult Blood Test (Hemoccult): An Update , 2008, The American Journal of Gastroenterology.

[3]  M. Kattan,et al.  Nomogram use for the prediction of indolent prostate cancer , 2007, Cancer.

[4]  M. Roobol,et al.  Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam. , 2007, Journal of the National Cancer Institute.

[5]  J. Habbema,et al.  Side‐effects of treatment for localized prostate cancer: are they valued differently by patients and healthy controls? , 2007, BJU international.

[6]  M. Roobol,et al.  A comparison of first and repeat (four years later) prostate cancer screening in a randomized cohort of a symptomatic men aged 55–75 years using a biopsy indication of 3.0 ng/ml (results of ERSPC, Rotterdam) , 2006, The Prostate.

[7]  E W Steyerberg,et al.  Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. , 2006, The Journal of urology.

[8]  J. Hugosson,et al.  Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study. , 2005, Archives of internal medicine.

[9]  M. Roobol,et al.  Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam). , 2005, Urology.

[10]  J. Adolfsson,et al.  Monitoring the ERSPC trial , 2003, BJU international.

[11]  J. Coebergh,et al.  Determining the cause of death in randomized screening trial(s) for prostate cancer , 2003, BJU International.

[12]  P. Smith,et al.  The Data Monitoring Committee – bridging the gap between urology and public health epidemiology , 2003, BJU international.

[13]  H. D. de Koning,et al.  Including the quality‐of‐life effects in the evaluation of prostate cancer screening: expert opinions revisited? , 2003, BJU international.

[14]  H. D. de Koning,et al.  Measuring disease specific quality of life in localized prostate cancer: The Dutch experience , 2003, Quality of Life Research.

[15]  T. Tammela,et al.  Acceptability and complications of prostate biopsy in population-based PSA screening versus routine clinical practice: a prospective, controlled study. , 2002, Urology.

[16]  M. Roobol,et al.  Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. , 2002, Urology.

[17]  H. D. de Koning,et al.  Prostate cancer mortality reduction by screening: Power and time frame with complete enrollment in the European randomised screening for prostate cancer (ERSPC) trial , 2002, International journal of cancer.

[18]  H. D. de Koning,et al.  Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Fritz H. Schröder,et al.  Evaluation of the Digital Rectal Examination as a Screening Test for Prostate Cancer , 1998 .

[20]  H. D. de Koning,et al.  Short-term effects of population-based screening for prostate cancer on health-related quality of life. , 1998, Journal of the National Cancer Institute.

[21]  G P Murphy,et al.  Report of the consensus workshop on screening and global strategy for prostate cancer , 1995, Cancer.

[22]  M. Stampfer,et al.  A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. , 1995, JAMA.

[23]  P. Knekt,et al.  Serum concentrations of prostate specific antigen and its complex with α1-antichymotrypsin before diagnosis of prostate cancer , 1994, The Lancet.

[24]  W. Catalona,et al.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.

[25]  T. Stamey,et al.  Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. , 1988, The New England journal of medicine.

[26]  P. O'Brien,et al.  A multiple testing procedure for clinical trials. , 1979, Biometrics.

[27]  O. Aalen.  Nonparametric Inference for a Family of Counting Processes , 1978 .

[28]  C. Lawton,et al.  Screening and Prostate-Cancer Mortality in a Randomized European Study , 2010 .

[29]  Stella R. Quah,et al.  International encyclopedia of public health , 2008 .

[30]  Hans Lilja,et al.  PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. , 2007, International journal of cancer.

[31]  H. D. de Koning,et al.  Prostate cancer diagnosis: the impact on patients' mental health. , 2006, European journal of cancer.

[32]  D. Chan,et al.  Hybritech total and free prostate-specific antigen assays developed for the Beckman Coulter access automated chemiluminescent immunoassay system: a multicenter evaluation of analytical performance. , 2001, Clinical Chemistry.

[33]  T. H. van der Kwast,et al.  Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination. , 2001, Urology.

[34]  I. McKeague.  Introduction to Aalen (1978) Nonparametric Inference for a Family of Counting Processes , 1997 .

[35]  T. Stamey,et al.  Making the most out of six systematic sextant biopsies. , 1995, Urology.

[36]  J. Higginson,et al.  International Agency for Research on Cancer. , 1968, WHO chronicle.